Transcutaneous bilirubin measurement system for infants

Country of origin  | United States of America

Health problem addressed
Hyperbilirubinæmia is a common condition in many newborns, affecting nearly 1 in 10 newborns and nearly 90% of premature infants in the first week of life. If undetected and untreated the levels of bilirubin may rise high enough to pass through the blood brain barrier and is deposited in the brain causing kinkterus and brain damage.

Product description
The device provides a numerical measurement of predicted bilirubin count in mg/dL or mol/L within a clinically beneficial range that has been correlated with total serum bilirubin concentration measured by High Pressure Liquid Chromatography (HPLC).

Product functionality
The device works by directing white light into the skin of the newborn and measuring the intensity of the specific wavelengths that are returned. By knowing the spectral properties of the components within the skin, one can subtract out the interfering components and determine the concentration of bilirubin.

Developer’s claims of product benefits
The technology of the device evaluates melanin, collagen, hemoglobin and bilirubin in a patient’s subcutaneous tissues through a proprietary algorithm and optics system. Existing technologies measure the yellowness of the skin as it relates to jaundice.

Operating steps
Simple button push for calibration, place on infants head or sternum and press the measurement button 5 times in succession and the results appears on the screen. Test taken in minutes.

Development stage
This product has been sold globally since 2002. To date over over 5000 units have been delivered to hospitals, clinics, physicians and community health workers.

Technical evaluation and health technology assessment review: FDA 510K  # k010052.
Regulatory approval complete. Conformity assessment has been carried out (USA).

Future work and challenges
The product is not registered as a medical device in all countries. Depending on the country of use, the product may need to be registered before it is used.

Use and maintenance
User: Nurse, midwife, physician
Training: Technique education on how to properly take a measurement.
Maintenance: Manufacturer

Environment of use
Setting: Rural and urban health care facilities.
Requirements: Power supply to charge the battery, disposal of calibration tip and cleansing products for pre-patient use.

Product specifications
Dimensions (mm): 204.5 x 50.23 x 59.4
Weight (kg): 0.346
Consumables: Disposable calibration tip (per test)
Life time: 5 years
Shelf life: 20 months
Retail Price (USD): 3500
List price (USD): 4295
List price of consumables (USD): approx. 360 (bag of 50)
Other features: Portable and reusable. Runs on batteries and uses software.
Year of commercialization: 2009 (first version in 1996)
Currently sold in: Most of Europe, as well as in Australia and several African, Asian, North- and South-American countries (65 countries).

Contact details  Jim McKenzie  Email susan.jones115@virginmedia.com  Telephone +1 412 380 8882  Fax +1 412 380 8850

Disclaimer

Eligibility for inclusion in the compendium has been evaluated by EuroScan member agencies and WHO. However, the evaluation by EuroScan member agencies and WHO has been solely based on a limited assessment of data and information submitted in the developers’ applications and, where available, of additional sources of evidence, such as literature search results or other publicly available information. There has been no rigorous review for safety, efficacy, quality, applicability, nor cost acceptability of any of the technologies. Therefore, inclusion in the compendium does not constitute a warranty of the fitness of any technology for a particular purpose. Besides, the responsibility for the quality, safety and efficacy of each technology remains with the developer and/or manufacturer. The decision to include a particular technology in the compendium is subject to change on the basis of new information that may subsequently become available to WHO. WHO will not be held to endorse nor to recommend any technology included in the compendium. Inclusion in the compendium solely aims at drawing stakeholders’ attention to innovative health technologies, either existing or under development, with a view to fostering the development and availability of, and/or access to, new and emerging technologies which are likely to be accessible, appropriate and affordable for use in low- and middle-income countries.

WHO does not furthermore warrant or represent that:

1. the list of new and emerging health technologies is exhaustive or error free; and/or that
2. the technologies which are included in the compendium will be embodied in future editions of the compendium; and/or that
3. the use of the technologies listed is, or will be, in accordance with the national laws and regulations of any country, including but not limited to patent laws; and/or that
4. any product that may be developed from the listed technologies will be successfully commercialized in target countries or that WHO will finance or otherwise support the development or commercialization of any such product.

WHO disclaims any and all liability and responsibility whatsoever for any injury, death, loss, damage or other prejudice of any kind whatsoever that may arise as a result of, or in connection with, the procurement, distribution and/or use of any technology embodied in the compendium, or of any resulting product and any future development thereof.